Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Neuropathologica Communications
Published in: Acta Neuropathologica Communications 1/2018

Open Access 01-12-2018 | Letter to the Editor

Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts

Authors: Julieann Lee, Angelica R. Putnam, Samuel H. Chesier, Anuradha Banerjee, Corey Raffel, Jessica Van Ziffle, Courtney Onodera, James P. Grenert, Boris C. Bastian, Arie Perry, David A. Solomon

Published in: Acta Neuropathologica Communications | Issue 1/2018

Login to get access

Excerpt

The genetic alterations that characterize oligodendroglial neoplasms have been defined over the past decade. In adults, oligodendrogliomas are genetically defined by the combination of IDH1 p.R132 or IDH2 p.R172 mutation, TERT promoter hotspot mutation (either c.-124C > T or c.-126C > T), and chromosomes 1p and 19q co-deletion, which is frequently accompanied by mutations involving CIC, FUBP1, TCF12, NOTCH1, and PIK3CA genes [2, 3, 7, 13, 21]. Oligodendrogliomas in children often lack the IDH mutation, TERT promoter mutation, and 1p/19q-codeletion that is observed in their adult counterparts [14, 20]. Instead, they most commonly harbor solitary pathogenic alterations in the FGFR1 oncogene that cause constitutive activation of the kinase domain via gene fusion, tandem duplication, or missense mutations that localize at one of two hotspots (p.N546 or p.K656) [18, 23]. …
Appendix
Available only for authorised users
Literature
1.
Bandopadhayay P, Ramkissoon LA, Jain P et al (2016) MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet 48:273–282CrossRef
2.
Bettegowda C, Agrawal N, Jiao Y et al (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333:1453–1455CrossRef
3.
Cancer Genome Atlas Research Network (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498CrossRef
4.
Ceccarelli M, Barthel FP, Malta TM et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563CrossRef
5.
Davis CF, Ricketts CJ, Wang M et al (2014) The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26:319–330CrossRef
6.
Diplas BH, He X, Brosnan-Cashman JA et al (2018) The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nat Commun 9:2087CrossRef
7.
Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508CrossRef
8.
Goode B, Mondal G, Hyun M et al (2018) A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. Nat Commun 9:810CrossRef
9.
Iorgulescu JB, Van Ziffle J, Stevers M et al (2018) Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. Acta Neuropathol 135:635–638CrossRef
10.
Killela PJ, Reitman ZJ, Jiao Y et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110:6021–6026CrossRef
11.
Kline CN, Joseph NM, Grenert JP et al (2017) Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro-Oncol 19:699–709PubMed
12.
Koelsche C, Sahm F, Capper D et al (2013) Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 126:907–915CrossRef
13.
Labreche K, Simeonova I, Kamoun A et al (2015) TCF12 is mutated in anaplastic oligodendroglioma. Nat Commun 6:7207CrossRef
14.
Nauen D, Haley L, Lin MT et al (2016) Molecular analysis of pediatric oligodendrogliomas highlights genetic differences with adult counterparts and other pediatric gliomas. Brain Pathol 26:206–214CrossRef
15.
Peifer M, Hertwig F, Roels F et al (2015) Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 526:700–704CrossRef
16.
Pekmezci M, Stevers M, Phillips JJ et al (2018) Multinodular and vacuolating neuronal tumor of the cerebrum is a clonal neoplasm defined by genetic alterations that activate the MAP kinase signaling pathway. Acta Neuropathol 135:485–488CrossRef
17.
Pekmezci M, Villanueva-Meyer JE, Goode B et al (2018) The genetic landscape of ganglioglioma. Acta Neuropathol Commun 6:47CrossRef
18.
Qaddoumi I, Orisme W, Wen J et al (2016) Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol 131:833–845CrossRef
19.
Ramkissoon LA, Horowitz PM, Craig JM et al (2013) Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A 110:8188–8193CrossRef
20.
Rodriguez FJ, Tihan T, Lin D (2014) Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients. Am J Surg Pathol 38:1058–1070CrossRef
21.
Suzuki H, Aoki K, Chiba K et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468CrossRef
22.
Valentijn LJ, Koster J, Zwijnenburg DA et al (2015) TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet 47:1411–1414CrossRef
23.
Zhang J, Wu G, Miller CP et al (2013) Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45:602–612CrossRef
Metadata
Title
Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts
Authors
Julieann Lee
Angelica R. Putnam
Samuel H. Chesier
Anuradha Banerjee
Corey Raffel
Jessica Van Ziffle
Courtney Onodera
James P. Grenert
Boris C. Bastian
Arie Perry
David A. Solomon
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Acta Neuropathologica Communications / Issue 1/2018
Electronic ISSN: 2051-5960
DOI
https://doi.org/10.1186/s40478-018-0598-x

Other articles of this Issue 1/2018

Acta Neuropathologica Communications 1/2018 Go to the issue

Research

Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma

Research

Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease

Research

Doublecortin-expressing cell types in temporal lobe epilepsy

Research

Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers

Research

Transcriptomic and epigenetic profiling of ‘diffuse midline gliomas, H3 K27M-mutant’ discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location

Research

Exosomes taken up by neurons hijack the endosomal pathway to spread to interconnected neurons